Avalon Trust Co Has $23.22 Million Holdings in VanEck Pharmaceutical ETF (NASDAQ:PPH)

Avalon Trust Co trimmed its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 0.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 285,375 shares of the company’s stock after selling 2,200 shares during the quarter. VanEck Pharmaceutical ETF accounts for 2.1% of Avalon Trust Co’s investment portfolio, making the stock its 14th largest holding. Avalon Trust Co owned 5.50% of VanEck Pharmaceutical ETF worth $23,220,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PPH. Raymond James Financial Services Advisors Inc. boosted its stake in VanEck Pharmaceutical ETF by 462.4% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 18,148 shares of the company’s stock valued at $1,477,000 after purchasing an additional 14,921 shares during the last quarter. Private Client Services LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the fourth quarter valued at approximately $298,000. GSA Capital Partners LLP grew its holdings in VanEck Pharmaceutical ETF by 12.6% during the third quarter. GSA Capital Partners LLP now owns 13,210 shares of the company’s stock worth $1,055,000 after buying an additional 1,480 shares in the last quarter. Allworth Financial LP purchased a new stake in VanEck Pharmaceutical ETF in the 4th quarter valued at $28,000. Finally, Conservest Capital Advisors Inc. bought a new position in VanEck Pharmaceutical ETF during the 4th quarter valued at $447,000.

VanEck Pharmaceutical ETF Price Performance

Shares of NASDAQ PPH traded down $0.30 during trading on Friday, hitting $87.11. The stock had a trading volume of 111,114 shares, compared to its average volume of 140,129. The firm has a fifty day moving average of $88.43 and a two-hundred day moving average of $83.92. The company has a market capitalization of $500.01 million, a PE ratio of 20.57 and a beta of 0.72. VanEck Pharmaceutical ETF has a 12 month low of $74.05 and a 12 month high of $91.16.

VanEck Pharmaceutical ETF Dividend Announcement

The company also recently disclosed a dividend, which was paid on Friday, April 5th. Shareholders of record on Tuesday, April 2nd were paid a $0.5328 dividend. The ex-dividend date of this dividend was Monday, April 1st.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.